Chemours Co (CC) Stock Rating Reaffirmed by Citigroup Inc

Citigroup Inc reaffirmed their neutral rating on shares of Chemours Co (NYSE:CC) in a research note issued to investors on Friday, April 14th. Citigroup Inc currently has a $40.00 price objective on the specialty chemicals company’s stock, up from their prior price objective of $34.00.

CC has been the subject of several other reports. Zacks Investment Research downgraded Chemours from a strong-buy rating to a hold rating in a report on Tuesday, January 17th. Susquehanna Bancshares Inc upgraded Chemours from a neutral rating to a positive rating and set a $40.00 price target for the company in a report on Friday, February 17th. Jefferies Group LLC upgraded Chemours from a hold rating to a buy rating and raised their price target for the company from $35.00 to $48.00 in a report on Wednesday, March 29th. Finally, Goldman Sachs Group Inc upgraded Chemours from a neutral rating to a buy rating in a report on Monday, February 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $37.70.

Chemours (NYSE:CC) traded up 2.48% during mid-day trading on Friday, hitting $43.81. 1,410,506 shares of the stock traded hands. Chemours has a 1-year low of $5.82 and a 1-year high of $46.02. The firm has a market capitalization of $8.08 billion, a P/E ratio of 76.59 and a beta of 3.50. The company has a 50-day moving average of $39.42 and a 200 day moving average of $30.01.

Chemours (NYSE:CC) last issued its quarterly earnings results on Monday, May 1st. The specialty chemicals company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.25. Chemours had a return on equity of 81.19% and a net margin of 2.78%. The firm had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period last year, the company earned $0.06 earnings per share. The company’s revenue was up 10.8% on a year-over-year basis. On average, equities research analysts anticipate that Chemours will post $3.26 EPS for the current year.

WARNING: “Chemours Co (CC) Stock Rating Reaffirmed by Citigroup Inc” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/05/19/chemours-co-cc-stock-rating-reaffirmed-by-citigroup-inc-updated-updated-updated.html.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Wednesday, May 17th will be paid a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date is Monday, May 15th. Chemours’s payout ratio is 14.81%.

In other Chemours news, VP Erich Parker sold 4,908 shares of the company’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Mark Newman sold 22,781 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $39.83, for a total value of $907,367.23. The disclosure for this sale can be found here. Insiders own 0.78% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. LS Investment Advisors LLC boosted its stake in shares of Chemours by 3.9% in the third quarter. LS Investment Advisors LLC now owns 6,997 shares of the specialty chemicals company’s stock valued at $112,000 after buying an additional 265 shares in the last quarter. Ropes Wealth Advisors LLC boosted its stake in shares of Chemours by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares in the last quarter. Schroder Investment Management Group purchased a new stake in shares of Chemours during the first quarter valued at $156,000. Cypress Capital Management LLC WY boosted its stake in shares of Chemours by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares in the last quarter. Finally, Clean Yield Group purchased a new stake in shares of Chemours during the first quarter valued at $167,000. 74.71% of the stock is currently owned by institutional investors.

About Chemours

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

5 Day Chart for NYSE:CC

What are top analysts saying about Chemours Co? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Co and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit